You are here: Industry Insights > WOCKHARDT

News List

Wockhardt and Jemincare partner for novel respiratory antibiotic Nafithromycin firstwordpharma
August 27, 2021
Wockhardt Bio AG – a subsidiary of Wockhardt Limited, (“Wockhardt”), a worldwide leader in discovery of novel antibiotics and Jiangxi Jemincare Group Company Limited, China (“Jemincare”), have partnered for Wockhardt’s novel patented antibiotic WCK 4873.
UK government extends contract with Wockhardt to fill-finish COVID-19 vaccines expresspharma
February 25, 2021
This expands the original agreement from 18 to 24 months i.e., until August 2022 and the manufacturing will continue to be undertaken at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales.
UK PM visits Wockhardt facility in North Wales expresspharma
December 02, 2020
The UK Government has reserved one fill and finish production line at Wockhardt UK for its exclusive use for 18 months in order to guarantee the supply of vaccines required to fight against COVID-19.
UK government reserves Wockhardt production line to fill finish COVID-19 vaccines europeanpharmaceuticalreview
August 05, 2020
The UK government reserved a production line at Wockhardt for 18 months to ensure the rapid fill finish of COVID-19 vaccines.
UK teams up with Wockhardt for vaccine manufacturing services pharmaceutical-technology
August 04, 2020
The UK Government has partnered with India-based pharmaceutical company Wockhardt for ‘fill and finish’ services to boost vaccine manufacturing in the UK.
Wockhardt signs partnership with UK Government to fill-finish COVID-19 vaccine expresspharma
August 04, 2020
The manufacturing will be undertaken at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales.
Dr Reddy’s Laboratories completes acquisition of Wockhardt’s select business divisions expresspharma
June 11, 2020
The acquired divisions comprise a portfolio of 62 brands in multiple therapy areas such as respiratory, neurology, VMS, dermatology, gastroenterology, pain and vaccines.
Wockhardt Q4 results: Firm posts profit of Rs 69 crore after loss in Q4FY19 expresspharma
May 12, 2020
Consolidated total income of the company stood at Rs 700.66 crore for the quarter under review. It was Rs 866.76 crore in the year-ago period.
Wockhardt receives US FDA Qualified Infectious Disease Product designation for WCK 6777 expresspharma
April 20, 2020
Pharmaceutical and biotechnology major Wockhardt has received the Qualified Infectious Disease Product (‘QIDP’) designation for WCK 6777 from the United States Food and Drug Administration (‘USFDA’).
Wockhardt Q1 net loss narrows to Rs 45 crore expresspharma
August 15, 2019
Wockhardt has reported narrowing of its consolidated net loss to Rs 44.98 crore for the quarter ended June 30, 2019. The company had posted a net loss of Rs 89.18 crore in the same period a year ago.

Previous page 1 2 Next page